v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | EUCTR2020-001928-34-SE |
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001928-34/SE |
First author
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
|
Contact
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
gunilla.wahlstrom@capiostgoran.se |
Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
2020-04-24 |
Recruitment status
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Terminated |
Study design
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Randomized |
Design
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Open label |
Center
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Treatment |
Inclusion criteria
Last imported at : Dec. 10, 2020, 1:30 a.m. Source : EU Clinical Trials Register |
1. Patients 18 years or older, who have signed informed consent for participation in the study 2. Hospitalized patients who have received oxygen therapy for maximum 48 hours 3. Verified Covid-19: Positive test for Sars-Cov-2-RNA or a positive Sars-Cov2 antigen test from upper respiratory tract 4. Receives oxygen therapy 5. Negative pregnancy test (female subjects of childbearing potential) 6. Female subjects of childbearing potential must use contraceptive method categorized as 'highly effective' according to CTFG during study treatment and 7 days after finished treatment. 1. Patienter 18 år eller äldre, som har givit sitt skriftliga samtycke till att delta i studien. 2. Vårdas inneliggande på sjukhus och har haft behandling med syrgas i maximalt 48 timmar 3. Verifierad Covid-19: Positivt prov för Sars-Cov2-RNA eller ett positivt Sars-Cov2 antigentest från övre luftvägar, det vill säga nasofarynx eller sputa. 4. Erhåller syrgasbehandling. 5. Negativt graviditetsprov (kvinnliga forskningspersoner i fertil ålder) 6. Villig att utöva antikonception kategoriserat som ”mycket effektiva” enligt Clinical Trial Facilitation Group under pågående studiebehandling + 7 dygn. (kvinnliga forskningspersoner i fertil ålder) |
Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
1. Pregnancy, breast feeding or plans for pregnancy. 2. Known intolerance or hypersensitivity to ciclesonide or any of the other components of the study drug 3. Concomitant treatment with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir 4. Therapy with >8 L oxygen/min or therapy with >50 % oxygen through high flow nasal cannula 5. Ongoing palliative treatment or life expectancy less than 72 hours 6. Expected admission to ICU within 48 hours 7. Active or inactive tuberculosis 8. Severe liver disease (Child-Pugh C) 9. Pulmonary arterial hypertension (PAH) or fibrosis 10. Mental incapacity, unwillingness or language difficulties 11. Participation in another clinical trial within 30 days before inclusion in the present study. Earlier participation in the present study. 1. Graviditet, amning eller planerad graviditet. 2. Överkänslighet mot ciklesonid eller mot något hjälpämne. 3. Samtidig medicinering med kortison, ketokonazol, itrakonazol, ritonavir eller nelfinavir. 4. Behandling med >8 l syrgas /min eller tillförsel av >50 % syrgas med nasal högflödesgrimma 5. Pågående palliativt inriktad vård eller förväntad överlevnad mindre än 72 timmar. 6. Förväntad inskrivning på intensivvårdsavdelning inom 48 timmar. 7. Aktiv eller inaktiv lungtuberkulos. 8. Grav leversvikt (Child-Pugh C) 9. Diagnosticerad med pulmonell arteriell hypertension (PAH) eller fibros. 10. Mental oförmåga, ovilja eller språksvårigheter som medför svårighet att förstå innebörden av att delta i studien. 11. Deltar eller nyligen deltagit eller i en klinisk läkemedelsprövning den senaste 30 dagarna. Tidigare deltagande i denna studie. |
Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
2 |
Funding
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Capio S:t Görans Sjukhus |
Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
100 |
Countries
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Sweden |
Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Moderate disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
3: Moderate disease at enrollment |
Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
446 |
primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Number of days with oxygen therapy (30 days follow up after study inclusion). Terminated oxygen therapy is defined as discharge from hospital, without subsequent rehospitalization with oxygen therapy within 2 days, or at least 2 days without oxygen therapy for hospitalized patients. Antal dygn med syrgasbehandling (30 dagars uppföljning efter studieinklusion). Avslutad syrgasbehandling definieras som utskrivning till hemmet utan en återinskrivning med syrgasbehandling inom 2 dygn eller minst 2 dygn utan syrgasbehandling vid inneliggande vård. Det primära utfallsmåttet representerar ”klinisk förbättring” enligt en nominell skala som använts i tidigare studier på behandling av Covid-19 och som rekommenderas av WHO. |
Notes
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
TODO |
Phase
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
[{"arm_notes": null, "treatment_id": 282, "treatment_name": "Ciclesonide", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": null, "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |